Toxicological Studies on An Anticancer Drug (HESA-A) with Marine OriginValiollah Hajhashemi1, Taghi Ghafghazi1, Mehdi Balali2, Amrollah Ahmadi1, Mashollah Taher3, Parvin Rajabi4, Ardeshir Talabi41Department of Pharmacology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran. 2Department of Toxicology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 3Department of Biochemistry, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran. 4Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
HESA-A, which contains biologically active compounds of marine origin, has selective toxicity against cancer cells. The present work reports the results of studies investigating the acute and sub-acute oral toxicity of this drug in mice and rats. In acute toxicity study, doses of HESA-A up to 13.7 g/kg and in sub-acute study, oral doses of 1250, 2500 and 5000 mg/kg for 30 consecutive days did not cause any morbidity or mortality. Data analysis of body weight gain, gross observations, blood biochemistry, hematology and histopathological findings did not show significant differences between control and treated groups. An oral dose of 5000 mg/kg of HESA-A can be defined as no-observed-adverse-effectlevel (NOAEL) for mice and rats used under the experimental conditions. Keywords: Anticancer, HESA-A, toxicity.
Valiollah Hajhashemi, Taghi Ghafghazi, Mehdi Balali, Amrollah Ahmadi, Mashollah Taher, Parvin Rajabi, Ardeshir Talabi. Toxicological Studies on An Anticancer Drug (HESA-A) with Marine Origin. Med J Islamic World Acad Sci. 2001; 14(4): 145-149
Corresponding Author: Valiollah Hajhashemi, Iran |
|